Fremanezumab as a preventive treatment for episodic and chronic migraine
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2019.1614742
Abstract: ABSTRACT Introduction: The importance of calcitonin gene-related peptide (CGRP) in migraine pathogenesis is well established. Fremanezumab is a humanized IgG2a monoclonal antibody that binds to CGRP. Areas covered: In this paper, we review the development… read more here.
Keywords: migraine; treatment episodic; episodic chronic; fremanezumab preventive ... See more keywords
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
Sign Up to like & getrecommendations! Published in 2023 at "Cephalalgia"
DOI: 10.1177/03331024221128250
Abstract: Background Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the long-term safety and tolerability of… read more here.
Keywords: safety; treatment episodic; trial; week ... See more keywords
Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s348724
Abstract: Abstract Advances in molecular biology and neuroscience have led to the discovery of calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide that plays a critical role in the pathogenesis of migraine. CGRP receptor antagonist, also… read more here.
Keywords: treatment episodic; role; atogepant treatment; role atogepant ... See more keywords